Europe CRISPR Gene Detection and Diagnostics Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-31
- Report ID: 144009
- Pages: 225
-
Format:
Short Description
Europe CRISPR Gene Detection and Diagnostic Market, By Class (Class 1- Multiple Effector Proteins and Class 2 -Single CrRNA-Binding Protein), Products & Services (Products and Services), Application (Biomedical Diagnostics, Genome Engineering, Drug Discovery, Agricultural Applications and Others), Workflow (Sample Preparation, Pre-Amplification, CrRNA, Cas Enzymes and Sensing), End User (Hospitals, Diagnostic Centers, Biotechnology Companies, Academic and Research Institutes and Others), Distribution Channel (Direct Tender, Retail Sales), Country (Germany, France, Italy U.K., Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Rest of Europe) Industry Trends and Forecast to 2029
Market Definition:
CRISPR is clustered regularly interspaced short palindromic repeats, is a tool for genome editing, meaning it allows researchers to easily alter DNA sequences and modify gene function. It has many potential applications, including correcting genetic defects, treating and preventing the spread of diseases. CRISPR-based diagnostics have been used for a wide range of biomedical applications, such as the sensing of nucleic-acid-based biomarkers of infectious and non-infectious diseases and for detection of genetic diseases. The assay kits in CRISPR is made up of two components: a protein called Cas9 and a guide RNA, a string of nucleic acid molecules with a certain genetic code.
This CRISPR-Cas9 system has been modified for use in mammalian cells. By introducing a guide sequence (sgRNA) specific for our gene of interest, we can either knock-out specific genes through introducing frame shift mutations via Non-Homologous End Joining (NHEJ), or generate knock-in mutations.
CRISPR-Cas 9 system have extended the scope of diagnostics and services for use in gene and cell therapies. Pharmaceutical companies are investing heavily in R&D to develop new products, with a surge of gene and cell therapy agents now entering early development. The market players are investing would allow to achieve the goal of producing safe and effective treatments for patients who are in serious need.
Market Segmentation:
The Europe CRISPR gene detection and diagnostic market is categorized into six segments: class, products and services, application, workflow, end user, and distribution channel.
On the basis of class, the Europe CRISPR gene detection and diagnostic market is segmented into class 1- multiple effector proteins and class 2 -single crRNA-binding protein
On the basis of products and services, the Europe CRISPR gene detection and diagnostic market is segmented into products and services
On the basis of application, the Europe CRISPR gene detection and diagnostic market is segmented into biomedical diagnostics, genome engineering, drug discovery, agricultural applications and others
On the basis of workflow, the Europe CRISPR gene detection and diagnostic market is segmented into sample preparation, pre-amplification, crRNA, cas enzymes and sensing
On the basis of end user, the Europe CRISPR gene detection and diagnostic market is segmented into hospitals, diagnostic centers, biotechnology companies, academic and research institutes and others
On the basis of distribution channel, the Europe CRISPR gene detection and diagnostic market is segmented into direct tenders, retail sales
Market Players
Some of the major players operating in the market are:
GenScript
OriGene Technologies, Inc.
Horizon Discovery Ltd
Agilent Technologies, Inc.
Merck KGaA
Integrated DNA Technologies, Inc. (A subsidiary of Danaher)
Thermo Fisher Scientific Inc.
Takara Bio Inc.
TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET 45
1.4 CURRENCY AND PRICING 47
1.5 LIMITATIONS 47
1.6 MARKETS COVERED 48
2 EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 DBMR TRIPOD DATA VALIDATION MODEL 54
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 57
2.6 MULTIVARIATE MODELLING 58
2.7 CLASS SEGMENT LIFELINE CURVE 58
2.8 DBMR MARKET POSITION GRID 59
2.9 VENDOR SHARE ANALYSIS 61
2.10 MARKET END USER COVERAGE GRID 62
2.11 SECONDARY SOURCES 63
3 EXECUTIVE SUMMARY 64
4 PREMIUM INSIGHTS 68
4.1 PESTEL 69
4.2 PORTER'S FIVE FORCES MODEL 70
5 INTELLECTUAL PROPERTY LANDSCAPE (PATENT LANDSCAPE) 71
6 EPIDEMIOLOGY 74
7 EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: REGULATORY SCENARIO 75
8 PIPELINE ANALYSIS FOR EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, OF CRISPR DIAGNOSTICS 77
9 MARKET OVERVIEW 78
9.1 DRIVERS 80
9.1.1 RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 80
9.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT 82
9.1.3 AVAILABILITY OF FUNDING FOR CRISPR GENE DIAGNOSTICS 83
9.1.4 RISE IN GMP-CERTIFICATION APPROVALS FOR CRISPR GENE DIAGNOSTIC 83
9.1.5 RISE IN CLINICAL TRIALS FOR CRISPR BASED DIAGNOSTICS 83
9.2 RESTRAINTS 84
9.2.1 RISE IN COST OF CRISPR BASED DIAGNOSTICS 84
9.2.2 RISKS FACED WHILE USING CRISPR DIAGNOSIS 84
9.2.3 ETHICAL CONCERNS RELATED TO CRISPR GENE DETECTION AND DIAGNOSTIC RESEARCH 85
9.2.4 AVAILABILITY OF ALTERNATIVES 85
9.3 OPPORTUNITIES 85
9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 85
9.3.2 RISE IN HEALTHCARE EXPENDITURE 86
9.3.3 EMERGENCE OF TECHNOLOGICAL ADVANCEMENTS IN CRISPR BASED DIAGNOSTICS 86
9.4 CHALLENGES 87
9.4.1 LACK OF SKILLED PROFESSIONALS REQUIRED FOR CRISPR DIAGNOSTICS 87
9.4.2 STRINGENT REGULATIONS 87
10 EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS 89
10.1 OVERVIEW 90
10.2 CLASS-2 SINGLE CRRNA-BINDING PROTEIN 93
10.2.1 BIOMEDICAL DIAGNOSTICS 94
10.2.2 AGRICULTURAL APPLICATIONS 94
10.2.3 GENOME ENGINEERING 94
10.2.4 DRUG DISCOVERY 94
10.2.5 OTHERS 94
10.3 CLASS-1 MULTIPLE EFFECTOR PROTEINS 95
11 EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES 96
11.1 OVERVIEW 97
11.2 PRODUCTS 100
11.2.1 ASSAY KITS 101
11.2.1.1 SGRNA KIT 101
11.2.1.2 GENOMIC DETECTION KIT 101
11.2.1.3 OTHERS 102
11.2.2 PROTEINS 102
11.2.2.1 CAS9 102
11.2.2.2 CPF1 102
11.2.2.3 OTHERS 102
11.2.3 PLASMID AND VECTOR 103
11.2.4 LIBRARY 103
11.2.5 CONTROL KITS 103
11.2.6 DELIVERY SYSTEM PRODUCTS 103
11.2.7 DESIGN TOOLS 103
11.2.8 GENOMIC RNA 103
11.2.9 HDR BLOCKERS 103
11.2.9.1 AZIDOTHYMIDINE 104
11.2.9.2 TRIFLUOROTHYMIDINE 104
11.2.9.3 OTHERS 104
11.2.9.4 OTHERS 104
11.3 SERVICES 104
11.3.1 G-RNA DESIGN 105
11.3.2 CELL LINE ENGINEERING 105
11.3.3 MICROBIAL GENE EDITING 105
11.3.4 DNA SYNTHESIS 106
11.3.5 OTHERS 106
12 EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION 107
12.1 OVERVIEW 108
12.2 BIOMEDICAL DIAGNOSTICS 111
12.2.1 CANCER 112
12.2.2 BLOOD DISORDERS 112
12.2.3 HEREDITARY DISORDERS 112
12.2.4 MUSCULAR DYSTROPHY 112
12.2.5 AIDS 112
12.2.6 NEURODEGENERATIVE CONDITION 112
12.2.7 OTHERS 113
12.3 AGRICULTURAL APPLICATIONS 113
12.4 GENOME ENGINEERING 113
12.4.1 CELL LINE ENGINEERING 114
12.4.2 HUMAN STEM CELLS 114
12.5 DRUG DISCOVERY 115
12.6 OTHERS 116
13 EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW 117
13.1 OVERVIEW 118
13.2 CRRNA 121
13.3 CAS ENZYME 121
13.4 PRE-AMPLIFICATION 122
13.4.1 PCR 123
13.4.2 LAMP 123
13.4.3 RPA 123
13.5 SAMPLE PREPARATION 123
13.6 SENSING 124
13.6.1 FLUORESCENT PROBES 125
13.6.2 COLORIMETRIC 125
14 EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER 126
14.1 OVERVIEW 127
14.2 BIOTECHNOLOGY COMPANIES 130
14.3 ACADEMIC AND RESEARCH INSTITUTES 131
14.4 DIAGNOSTIC CENTERS 132
14.5 HOSPITALS 133
14.6 OTHERS 134
15 EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 135
15.1 OVERVIEW 136
15.2 DIRECT TENDER 140
15.3 RETAIL SALES 141
16 EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION 142
16.1 EUROPE 143
16.1.1 GERMANY 152
16.1.2 FRANCE 157
16.1.3 U.K. 162
16.1.4 ITALY 167
16.1.5 RUSSIA 172
16.1.6 SPAIN 177
16.1.7 NETHERLANDS 182
16.1.8 SWITZERLAND 187
16.1.9 BELGIUM 192
16.1.10 TURKEY 197
16.1.11 REST OF ASIA-PACIFIC 202
17 EUROPE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY LANDSCAPE 203
17.1 COMPANY SHARE ANALYSIS: EUROPE 203
18 SWOT ANALYSIS 204
19 COMPANY PROFILE 205
19.1 THERMO FISHER SCIENTIFIC INC. 205
19.1.1 COMPANY SNAPSHOT 205
19.1.2 REVENUE ANALYSIS 205
19.1.3 COMPANY SHARE ANALYSIS 206
19.1.4 PRODUCT PORTFOLIO 206
19.1.5 RECENT DEVELOPMENTS 207
19.2 MERCK KGA 208
19.2.1 COMPANY SNAPSHOT 208
19.2.2 REVENUE ANALYSIS 208
19.2.3 COMPANY SHARE ANALYSIS 209
19.2.4 PRODUCT PORTFOLIO 209
19.2.5 RECENT DEVELOPMENTS 210
19.3 AGILENT TECHNILOGIES, INC 212
19.3.1 COMPANY SNAPSHOT 212
19.3.2 REVENUE ANALYSIS 212
19.3.3 COMPANY SHARE ANALYSIS 213
19.3.4 PRODUCT PORTFOLIO 213
19.3.5 RECENT DEVELOPMENT 214
19.4 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER) 215
19.4.1 COMPANY SNAPSHOT 215
19.4.2 REVENUE ANALYSIS 215
19.4.3 COMPANY SHARE ANALYSIS 216
19.4.4 PRODUCT PORTFOLIO 216
19.4.5 RECENT DEVELOPMENTS 217
19.5 GENSCRIPT 218
19.5.1 COMPANY SNAPSHOT 218
19.5.2 REVENUE ANALYSIS 218
19.5.3 COMPANY SHARE ANALYSIS 219
19.5.4 PRODUCT PORTFOLIO 219
19.5.5 RECENT DEVELOPMENT 220
19.6 10 X GENOMICS 221
19.6.1 COMPANY SNAPSHOT 221
19.6.2 REVENUE ANALYSIS 221
19.6.3 PRODUCT PORTFOLIO 222
19.6.4 RECENT DEVELOPMENTS 222
19.7 APPLIED STEM CELL 223
19.7.1 COMPANY SNAPSHOT 223
19.7.2 PRODUCT PORTFOLIO 223
19.7.3 RECENT DEVELOPMENT 223
19.8 ADDGENE 224
19.8.1 COMPANY SNAPSHOT 224
19.8.2 PRODUCT PORTFOLIO 224
19.8.3 RECENT DEVELOPMENT 224
19.9 BIOVISION INC. 225
19.9.1 COMPANY SNAPSHOT 225
19.9.2 PRODUCT PORTFOLIO 225
19.9.3 RECENT DEVELOPMENT 226
19.10 CELLECTA, INC 227
19.10.1 COMPANY SNAPSHOT 227
19.10.2 PRODUCT PORTFOLIO 227
19.10.3 RECENT DEVELOPMENTS 228
19.11 CAS TAG BIOSCIENCES 229
19.11.1 COMPANY SNAPSHOT 229
19.11.2 PRODUCT PORTFOLIO 229
19.11.3 RECENT DEVELOPMENT 229
19.12 GENECOPOEIA, INC. 230
19.12.1 COMPANY SNAPSHOT 230
19.12.2 PRODUCT PORTFOLIO 230
19.12.3 RECENT DEVELOPMENT 230
19.13 HORIZON DISCOVERY LTD 231
19.13.1 COMPANY SNAPSHOT 231
19.13.2 PRODUCT PORTFOLIO 231
19.13.3 RECENT DEVELOPMENTS 232
19.14 HERA BIOLABS 233
19.14.1 COMPANY SNAPSHOT 233
19.14.2 PRODUCT PORTFOLIO 233
19.14.3 RECENT DEVELOPMENT 234
19.15 NEW ENGLAND BIOLABS 235
19.15.1 COMPANY SNAPSHOT 235
19.15.2 PRODUCT PORTFOLIO 235
19.15.3 RECENT DEVELOPMENTS 236
19.16 ORIGENE TECHNOLOGIES, INC. 237
19.16.1 COMPANY SNAPSHOT 237
19.16.2 PRODUCT PORTFOLIO 237
19.16.3 RECENT DEVELOPMENT 238
19.17 SYNTHEGO 239
19.17.1 COMPANY SNAPSHOT 239
19.17.2 PRODUCT PORTFOLIO 239
19.17.3 RECENT DEVELOPMENTS 239
19.18 TAKARA BIO INC. 241
19.18.1 COMPANY SNAPSHOT 241
19.18.2 REVENUE ANALYSIS 241
19.18.3 PRODUCT PORTFOLIO 242
19.18.4 RECENT DEVELOPMENT 242
19.19 TOOLGEN, INC. 243
19.19.1 COMPANY SNAPSHOT 243
19.19.2 PRODUCT PORTFOLIO 243
19.19.3 RECENT DEVELOPMENT 243
20 QUESTIONNAIRE 244
21 RELATED REPORTS 247
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
